Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Cancer discovery - 1 Feb 2020

Erkes Dan A, Cai Weijia, Sanchez Ileine M, Purwin Timothy J, Rogers Corey, Field Conroy O, Berger Adam C, Hartsough Edward J, Rodeck Ulrich, Alnemri Emad S, Aplin Andrew E

Abstract excerpt

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Dendritic Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Proof of Concept Study

Share to Skin Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 31796433
DOI: 10.1158/2159-8290.CD-19-0672
PMCID: PMC7007378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.PMID 31796433Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

Systemic effects of melanoma-secreted MIDKINE in the inhibition of dendritic cell differentiation and functionSemantic proximity Read ↗

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.Semantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant MelanomaSemantic proximity Read ↗

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?Semantic proximity Read ↗

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.Semantic proximity Read ↗

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.Semantic proximity Read ↗

Midkine Drives Reawakening of Dormant Melanoma MetastasesSemantic proximity Read ↗

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.Semantic proximity Read ↗

HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.